Cardiac Regeneration and Ion Channel Program

Hydra Biosciences, a biopharmaceutical company, develops novel drugs using its expertise in novel ion channels. The company is currently focused in major therapeutic areas: pain, inflammation, renal, anxiety and pulmonary disease.

Hydra's mission is to advance first in class therapeutics to address significant unmet medical needs, with our cutting edge research, technology, and development expertise. Hydra is pursuing opportunities from which it expects to advance a pipeline of clinically and commercially viable products and welcomes inquires into potential collaborations and partnerships.

The recently discovered Transient Receptor Potential (TRP) family of ion channels is an area of focus at Hydra. TRPs offer numerous drug discovery opportunities in multiple areas of human disease. Hydra is applying its state-of-the-art high throughput screening facility and substantial expertise in channel physiology to advance drug candidates in multiple areas including targets that have the potential to be used to treat many significant diseases.